Newsfeed : ATAC Releases Pharmaceutical Company HIV/AIDS Report Card

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Newsfeed » September 2009

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

September 10, 2009

ATAC Releases Pharmaceutical Company HIV/AIDS Report Card

On September 10, the AIDS Treatment Activists Coalition (ATAC) released September 10 a report card on the pharmaceutical industry that graded nine pharmaceutical companies on their drug development portfolio and plans, access to drugs, pricing, community relations and marketing practices around HIV,  The New York Times reports.

ATAC researched Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Pfizer, Roche and Tibotec Therapeutics over the course of the past year.

Merck and Tibotec scored the highest on the report card receiving Bs. Abbott scored the lowest, receiving an F.

As a group, the nine drugmakers received an average grade of C- which, according to Bob Huff, antiretroviral treatment director of the New York City–based Treatment Action Group and board member of the ATAC rating board, indicates room for improvement.

“There’s an opportunity now to kick it up a notch,” Huff told the Times. While ATAC receives funding from pharmaceutical companies, he affirmed that cash flow had no affect on the grading process. “There’s no sugarcoating,” he said. “The membership feels that the pharmaceutical industry can be doing a much better job, whether it’s innovation or pricing.”

Search: ATAT, report card, pharmaceutical, Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Pfizer, Roche, Tibotec Therapeutics, Treatment Action Group


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    dlw8585
    Fort Lauderdale
    Florida


    juliar33
    brooklyn
    New York


    hollywoodvers1
    Los Angeles
    California


    RayOctober
    Richmond
    Virginia
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Can social media help stop HIV stigma?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.